Prescription Drug Price Transparency

To increase transparency into the pricing of prescription drugs, the Minnesota Legislature passed and further amended the Minnesota Prescription Drug Price Transparency Act (the Act) requiring MDH to develop a system for collecting and reporting data from drug manufacturers, wholesalers, pharmacy benefit managers, and pharmacies on prescription drug prices (Minnesota Statutes 62J.84).

MDH will publicly post reported data on this website and produce an annual report to the legislature. In addition to synthesizing findings from data reporting, the goals of these efforts are to demonstrate how the initiative meets three goals of the law:

• Promote transparency in pharmaceutical pricing in Minnesota.
• Enhance the understanding of pharmaceutical spending trends.
• Assist the state and other payers in the management of pharmaceutical costs.

Please refer to this page to monitor progress, access resources, ask questions and sign up for our email updates for news and notifications.

NEW: The March 2025 List of Drugs of Substantial Public Interest was posted by MDH on March 12—see the March 2025 List of Drugs (Excel) and March 2025 Summary & Methodology (PDF).  Reporting entities will have approximately 90 days to report. For more information, visit the Drugs of Substantial Public Interest webpage.